Parkinson’s disease (PD) is a common and slow-progressing neurodegenerative disorder characterized by motor and non-motor symptoms, including gastrointestinal (GI) dysfunctions. Over the last years, the microbiota-gut-brain (MGB) axis is emerging as a bacterial-neuro-immune ascending pathway that contributes to the progression of PD. Indeed, PD patients are characterized by changes in gut microbiota composition, alterations of intestinal epithelial barrier (IEB) and enteric neurogenic/inflammatory responses that, besides determining intestinal disturbances, contribute to brain pathology. In this context, despite the causal relationship between gut dysbiosis, impaired MGB axis and PD remains to be elucidated, emerging evidence shows that MGB axis modulation can represent a suitable therapeutical strategy for the treatment of PD. This review provides an overview of the available knowledge about the beneficial effects of gut-directed therapies, including dietary interventions, prebiotics, probiotics, synbiotics and fecal microbiota transplantation (FMT), in both PD patients and animal models. In this context, particular attention has been devoted to the mechanisms by which the modulation of MGB axis could halt or slow down PD pathology and, most importantly, how these approaches can be included in the clinical practice.

Gut-directed therapy in Parkinson’s disease / Benvenuti, Laura; Di Salvo, Clelia; Bellini, Gabriele; Seguella, Luisa; Rettura, Francesco; Esposito, Giuseppe; Antonioli, Luca; Ceravolo, Roberto; Bernardini, Nunzia; Pellegrini, Carolina; Fornai, Matteo. - In: FRONTIERS IN PHARMACOLOGY. - ISSN 1663-9812. - (2024), pp. 1-22. [10.3389/fphar.2024.1407925]

Gut-directed therapy in Parkinson’s disease

Luisa Seguella;Giuseppe Esposito;
2024

Abstract

Parkinson’s disease (PD) is a common and slow-progressing neurodegenerative disorder characterized by motor and non-motor symptoms, including gastrointestinal (GI) dysfunctions. Over the last years, the microbiota-gut-brain (MGB) axis is emerging as a bacterial-neuro-immune ascending pathway that contributes to the progression of PD. Indeed, PD patients are characterized by changes in gut microbiota composition, alterations of intestinal epithelial barrier (IEB) and enteric neurogenic/inflammatory responses that, besides determining intestinal disturbances, contribute to brain pathology. In this context, despite the causal relationship between gut dysbiosis, impaired MGB axis and PD remains to be elucidated, emerging evidence shows that MGB axis modulation can represent a suitable therapeutical strategy for the treatment of PD. This review provides an overview of the available knowledge about the beneficial effects of gut-directed therapies, including dietary interventions, prebiotics, probiotics, synbiotics and fecal microbiota transplantation (FMT), in both PD patients and animal models. In this context, particular attention has been devoted to the mechanisms by which the modulation of MGB axis could halt or slow down PD pathology and, most importantly, how these approaches can be included in the clinical practice.
2024
Parkinson's disease, Gut, Therapy
01 Pubblicazione su rivista::01a Articolo in rivista
Gut-directed therapy in Parkinson’s disease / Benvenuti, Laura; Di Salvo, Clelia; Bellini, Gabriele; Seguella, Luisa; Rettura, Francesco; Esposito, Giuseppe; Antonioli, Luca; Ceravolo, Roberto; Bernardini, Nunzia; Pellegrini, Carolina; Fornai, Matteo. - In: FRONTIERS IN PHARMACOLOGY. - ISSN 1663-9812. - (2024), pp. 1-22. [10.3389/fphar.2024.1407925]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1712241
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact